Twelve months after revaccination, antibody levels declined but remained significantly higher than baseline in patients with CLL.

"When the first BTK inhibitor got approved by the FDA for other conditions, we all saw that follicular lymphoma should be the ...

Neurology experts from UCSF Health presented new clinical research findings and cutting-edge treatment strategies and received distinguished awards recognition at the American Academy of Neurology’s ...

EPALINGES, Switzerland and PARIS, April 22, 2025 /PRNewswire/ — Onward Therapeutics SA, a biotechnology company dedicated to advancing innovative cancer immunotherapies, announced that its subsidiary, ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

胰腺癌（PDAC）的免疫治疗效果不佳，肿瘤微环境（TME）是重要原因。为探究 TME 中 CD20 + B 细胞的临床意义，福建医科大学附属第一医院等机构的研究人员分析 45 例 PDAC 患者的切片。结果显示，侵袭前沿（IF）的 B 细胞分布特征与患者预后相关。该研究为胰腺癌预后评估提供新视角 129 。

Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from Egypt suggests.

In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile in adult patients with generalized myasthenia gravis, offering a promising ...

Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of ...

The ENHANCE Phase 3b clinical trial is evaluating the safety and efficacy of a modified treatment regimen of Briumvi for ...

Lyell Immunopharma (LYEL) announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy, RMAT, ...

Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...